

Jecure Therapeutics announces the appointment of Vice President for its Biology division

18 December 2017 | News

Dr. Bain is an accomplished biologist with more than fifteen years of experience in both biotech and pharmaceutical companies. She has deep expertise in the development of small-molecule drug candidates and has directed preclinical programs for idiopathic pulmonary fibrosis (IPF), NASH, systemic sclerosis, and chronic kidney disease indications.



Jecure Therapeutics, a biotechnology company with novel drug discovery programs targeting non-alcoholic steatohepatitis (NASH) and fibrosis has announced that Gretchen Bain, Ph.D., has joined the company as its Vice President of Biology.

Dr. Bain is an accomplished biologist with more than fifteen years of experience in both biotech and pharmaceutical companies. She has deep expertise in the development of small-molecule drug candidates and has directed preclinical programs for idiopathic pulmonary fibrosis (IPF), NASH, systemic sclerosis, and chronic kidney disease indications. Previous to Jecure, she was an Executive Director of Biology at PharmAkea Therapeutics and at Bristol-Myers Squibb, where she contributed to the discovery and development of multiple clinical-phase drugs to treat fibrosis.

"We are thrilled to welcome Gretchen to our management team," said Dr. Jeffrey Stafford, President and CEO of Jecure Therapeutics. "Her expertise in anti-fibrotics discovery research and clinical biomarker development is immediately impactful to Jecure's goal of advancing first-in-class NLRP3 inhibitors into the clinic."

Dr. Bain holds a Ph.D. in molecular and cellular biology from the University of California, San Diego, where she also completed a postdoctoral fellowship.